XTX Topco Ltd Buys Shares of 10,900 Foghorn Therapeutics Inc. (NASDAQ:FHTX)

XTX Topco Ltd purchased a new stake in shares of Foghorn Therapeutics Inc. (NASDAQ:FHTX) in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 10,900 shares of the company’s stock, valued at approximately $101,000.

A number of other institutional investors and hedge funds have also made changes to their positions in FHTX. Raymond James & Associates increased its holdings in Foghorn Therapeutics by 4.8% in the 2nd quarter. Raymond James & Associates now owns 2,338,423 shares of the company’s stock valued at $13,446,000 after purchasing an additional 107,967 shares during the last quarter. Bank of New York Mellon Corp raised its holdings in shares of Foghorn Therapeutics by 30.7% in the 2nd quarter. Bank of New York Mellon Corp now owns 79,433 shares of the company’s stock valued at $457,000 after buying an additional 18,664 shares during the period. Rhumbline Advisers lifted its stake in Foghorn Therapeutics by 34.3% during the 2nd quarter. Rhumbline Advisers now owns 35,910 shares of the company’s stock worth $206,000 after acquiring an additional 9,171 shares in the last quarter. Renaissance Technologies LLC purchased a new position in Foghorn Therapeutics during the 2nd quarter valued at about $62,000. Finally, Deerfield Management Company L.P. Series C acquired a new position in Foghorn Therapeutics in the 2nd quarter valued at about $14,481,000. 61.55% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on FHTX shares. HC Wainwright reissued a “buy” rating and set a $13.00 price target (down previously from $20.00) on shares of Foghorn Therapeutics in a research report on Tuesday, December 17th. Jefferies Financial Group reduced their target price on shares of Foghorn Therapeutics from $18.00 to $14.00 and set a “buy” rating on the stock in a report on Monday, December 16th. Finally, Morgan Stanley boosted their price target on shares of Foghorn Therapeutics from $6.00 to $9.00 and gave the stock an “equal weight” rating in a research note on Tuesday, September 24th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $13.80.

Foghorn Therapeutics Stock Up 3.2 %

Shares of Foghorn Therapeutics stock opened at $5.14 on Friday. Foghorn Therapeutics Inc. has a 52-week low of $2.70 and a 52-week high of $10.25. The company has a market capitalization of $285.75 million, a P/E ratio of -2.68 and a beta of 3.10. The company has a 50 day moving average of $7.50 and a 200 day moving average of $7.15.

Foghorn Therapeutics Profile

Foghorn Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system.